Perspectives
perspectives
July 7th, 2026
Don’t Veer for Deer: Why Drug Development Needs Steady Steering in the Age of AI and Real-Time Data.
perspectives
July 6th, 2026
How REMS Defines the Patient Journey in Psychedelic Therapies
perspectives
June 30th, 2026
The Future of Biostatistics: Insights from Presenters at PSI 2026
perspectives
June 11th, 2026
AI in Regulatory Strategy: Practical Uses for Submission Readiness
perspectives
June 3rd, 2026
What Pharma Can Learn from Data Science Outside the Industry
perspectives
May 19th, 2026
Turning Real-World Data into Reliable Evidence: The Role of Data Science
perspectives
May 13th, 2026
Beyond Data Cleaning: A Strategic Shift for Clinical Data Management under ICH E6 (R3)
perspectives
May 5th, 2026
A Statistician's Reflection: FDA Guidance on Limiting Crossover in Oncology Studies
perspectives
April 27th, 2026
From Stigma to Signal: The Executive Order, CNPV Vouchers, and What Comes Next for Psychedelics
perspectives
April 20th, 2026
The FDA Drug Shortage List Signals Deeper Concerns for the US Medicine Supply Chain
perspectives
April 15th, 2026
Decision-Making in Early-Phase Oncology Trials: Navigating Uncertainty with Evidence Frameworks
perspectives
April 8th, 2026
Four Pillars of My Success as a Clinical Trial Transparency Specialist